EN DE
Watch Rockwell Medical Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Rockwell Medical Inc (RMTI) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Rockwell Medical Inc stock $7.90, price $6.10, upside +29.5%, quality 41 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US7743743004

RM Rockwell Medical Inc logo Thin data Nov 14, 2026

Rockwell Medical Inc

RMTI · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value $7.90 · Fairly valued 
Quality 41/100 
Expensive Growth (revenue 5y +2.2 %/yr in USD) 
Insiders sold $8,420 (6M) 
Falling price (downtrend) 
Loss-making · -7.3% net margin (TTM) 
Negative free cash flow 
Trails peers (4/11) 
Narrow moat 16/100
Thin data 
Estimate
Watch Rockwell Medical Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$75.35 $1.82 Fair Value $7.90 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $1.82 – $75.35 · fair‑value band $5.93 – $9.88 · the $6.10 price screens below the $7.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Rockwell Medical in your weekly email

Every Wednesday you see whether Rockwell Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.

Show moreShow less

It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.

The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process.

The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Stock analysis

Rockwell Medical Inc (RMTI) currently trades at $6.10, while our estimate is $7.90, so the stock looks roughly fairly valued today (gap 22.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.93 (bear) to $9.88 (bull), the price of $6.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Rockwell Medical Inc reported revenue of $69.3M in FY2025 versus $61.9M in FY2021, a compound +2.8%/yr. Reported net income was −$5.3M in FY2025.

Key figures

Market cap $24.2M Micro · P/S ratio 0.40 · EPS (TTM) $−1.43 · Net margin −7.3% · Return on equity −15.5% · Return on assets (EBIT) −23.7% (5-year average) · Operating margin −6.5% · Revenue (TTM) $69.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 52% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 30%, RMTI screens cheaper than that median.

Fair Value

Bear $5.93 Fair Value $7.90 Bull $9.88
Price $6.10 · Upside +29.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 55
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $8,420 and none bought.

  • SaleMark StrobeckPresident and CEO, Director1,000 shares at $8.42$8,420Oct 1, 202610b5-1 plan
  • SaleJesse NeriSVP and CFO886 shares at $0.8400$744Jan 2, 202610b5-1 plan
  • SaleHeather HunterChief Operating Officer2,868 shares at $0.8400$2,409Jan 2, 202610b5-1 plan

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 18, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−31.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic). Over 10 years: +2.3% a year
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−45.7% (2020) → −6.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch RMTI, get fair value alerts →

Compare Rockwell Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside +29.5% · Top 25%
Profitability
Return on assets −9.3% · Bottom 25%
Net margin (12 months) −7.3% · Bottom 25%
Operating margin (12 months) −6.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 10.6% · Above median
Balance sheet
Debt / equity 0.24× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.66× · Cheapest 25%
P/S (12 months) 0.35× · Cheapest 25%
PEG 4.43× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)73 · sector 20
FUTURE (revenue growth)53 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)88 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs RMTI
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs RMTI
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs RMTI
Haleon plc HLN $9.08 $8.47 −7% vs RMTI
Merck KGaA MRK €148.40 €108.83 −27% vs RMTI
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs RMTI
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs RMTI
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs RMTI
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs RMTI
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs RMTI

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rockwell Medical Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rockwell Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/RMTI

Frequently asked questions

Is Rockwell Medical Inc (RMTI) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $7.90 versus a price of $6.10, about +30% upside (fairly valued).
What is the fair value of RMTI?
Our estimate for Rockwell Medical Inc is $7.90 (as of Nov 14, 2026), built from audited fundamentals. The current price: $6.10.
What is the quality score of RMTI?
Rockwell Medical Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rockwell Medical Inc (RMTI)?
We do not set a price target; the yardstick is our estimate of $7.90 (as of Nov 14, 2026). Cautious scenario $5.93, optimistic scenario $9.88. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Rockwell Medical Inc stock forecast for 2026?
Our estimate puts fair value at $7.90, about +30% upside versus a price of $6.10 (fairly valued). Cautious scenario $5.93, optimistic scenario $9.88. The calculation is refreshed regularly with new filings.
What is the revenue of Rockwell Medical Inc (RMTI)?
Rockwell Medical Inc reported trailing-twelve-month revenue of about $69.4M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Rockwell Medical Inc (RMTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rockwell Medical Inc it is $7.90 per share (as of Nov 14, 2026), against a price of $6.10.
Is Rockwell Medical Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, RMTI trades below its calculated fair value: price $6.10, fair value $7.90, a gap of about +30% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RMTI?
No. The price is what the market pays today ($6.10); the fair value is what the company's own numbers justify ($7.90). For Rockwell Medical Inc the two are $1.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rockwell Medical Inc worth?
The market values Rockwell Medical Inc at about $24.2M (market capitalisation, as of Nov 14, 2026). Per share that is $6.10; our models calculate a fair value of $7.90 per share.
What do the bullish and bearish scenarios say about RMTI?
Our models span a range for Rockwell Medical Inc: cautious scenario $5.93, base $7.90, optimistic $9.88 per share (as of Nov 14, 2026, price $6.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of RMTI?
The PEG ratio of Rockwell Medical Inc is 4.43 (P/E divided by earnings growth, as of Nov 14, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Rockwell Medical Inc (RMTI)?
Balance-sheet figures for Rockwell Medical Inc (as of Nov 14, 2026): return on equity −15.5%, debt of 0.24 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is RMTI from its 52-week high?
Rockwell Medical Inc trades at $6.10, about 52% below its 52-week high of $12.60 and 18% above the low of $5.19 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of $7.90 is for.
Which stocks are comparable to Rockwell Medical Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rockwell Medical Inc stock attractive at the current price?
The data as of Nov 14, 2026: price $6.10, calculated fair value $7.90 (+30%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Rockwell Medical Inc currently trades 23% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rockwell Medical Inc (RMTI)?
The closing price on Nov 18, 2026 was $6.10. Our estimate is $7.90, about +30% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rockwell Medical Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Rockwell Medical Inc

How large is the market capitalisation of Rockwell Medical Inc (RMTI)?
The market capitalisation of Rockwell Medical Inc is $24.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rockwell Medical Inc (RMTI)?
The price-to-sales ratio of Rockwell Medical Inc is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rockwell Medical Inc (RMTI)?
Earnings per share at Rockwell Medical Inc are $−1.43. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Rockwell Medical Inc (RMTI)?
The net margin of Rockwell Medical Inc is −7.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rockwell Medical Inc (RMTI)?
The return on equity (ROE) of Rockwell Medical Inc is −15.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rockwell Medical Inc (RMTI)?
On an EBIT basis the return on assets of Rockwell Medical Inc is −23.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rockwell Medical Inc (RMTI)?
The operating margin of Rockwell Medical Inc is −6.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rockwell Medical Inc (RMTI)?
Revenue at Rockwell Medical Inc is growing 10.6% versus a year earlier (3y avg −1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rockwell Medical Inc (RMTI) generate?
The free cash flow of Rockwell Medical Inc is −$1.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rockwell Medical Inc (RMTI) carry?
The net debt of Rockwell Medical Inc is $1.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rockwell Medical Inc in the live analysis

One click puts Rockwell Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.